Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

AJNR. American journal of neuroradiology - 1 Aug 2012

Carrillo J A, Lai A, Nghiemphu P L, Kim H J, Phillips H S, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson B M, Cloughesy T F, Pope W B

Abstract excerpt

BACKGROUND AND PURPOSE: Both IDH1 mutation and MGMT promoter methylation are associated with longer survival. We investigated the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes. MATERIALS AND METHODS: MR imaging from 202 patients with GBM was retrospectively assessed for nonenhancing tumor and edema among other imaging features. IDH1 mutational and MGMT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Edema
Share to California

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Comorbidity

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Statistics as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 22322613
DOI: 10.3174/ajnr.A2950
PMCID: PMC7965490

Genes

IDH1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.PMID 22322613Read ↗

Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.Semantic proximity Read ↗

Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity imageSemantic proximity Read ↗

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype GlioblastomaSemantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.Semantic proximity Read ↗

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1Semantic proximity Read ↗

Histological grade 2 and non-contrast-enhancing phenotype provide prognostic information complementary to DNA methylation classification in TERTp-mutant molecular glioblastomas.Semantic proximity Read ↗

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Semantic proximity Read ↗

Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomasSemantic proximity Read ↗

Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasSemantic proximity Read ↗

Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.Semantic proximity Read ↗

The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.